Chamberlin J, Laughlin L, Gordon S, Romero S, Solórzano N, Regnery R L
Department of Preventive Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
J Clin Microbiol. 2000 Nov;38(11):4269-71. doi: 10.1128/JCM.38.11.4269-4271.2000.
Bartonella bacilliformis causes bartonellosis, a potentially life-threatening emerging infectious disease seen in the Andes Mountains of South America. There are no generally accepted serologic tests to confirm the disease. We developed an indirect fluorescence antibody (IFA) test for the detection of antibodies to B. bacilliformis and then tested its performance as an aid in the diagnosis of acute bartonellosis. The IFA is 82% sensitive in detecting B. bacilliformis antibodies in acute-phase blood samples of laboratory-confirmed bartonellosis patients. When used to examine convalescent-phase sera, the IFA is positive in 93% of bartonellosis cases. The positive predictive value of the test is 89% in an area of Peru where B. bacilliformis is endemic and where the point prevalence of infection is 45%.
杆状巴尔通体可引发巴尔通体病，这是一种在南美洲安第斯山脉出现的潜在威胁生命的新发传染病。目前尚无普遍认可的血清学检测方法来确诊该病。我们开发了一种间接荧光抗体（IFA）检测法用于检测抗杆状巴尔通体抗体，然后测试其作为辅助诊断急性巴尔通体病的性能。IFA在检测实验室确诊的巴尔通体病患者急性期血样中的抗杆状巴尔通体抗体时，敏感性为82%。当用于检测恢复期血清时，IFA在93%的巴尔通体病病例中呈阳性。在秘鲁杆状巴尔通体为地方病且感染点患病率为45%的地区，该检测的阳性预测值为89%。
